AMW welcomes Ilse Aigner, President of the Bavarian State Parliament, at the Warngau site to share a success story

Warngau, Germany, April 11, 2024 AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, was delighted to welcome today the President of the Bavarian State Parliament, Ilse Aigner, to its headquarters in Warngau near Munich, Germany. In her speech to AMW employees, Ms. Aigner acknowledged the Company’s innovative strength and emphasized […]

read more

AMW Further Strengthens Executive Leadership Team by Appointing Dr. Joerg Serafimov as Chief Business Officer

Warngau, January 9, 2024 AMW GmbH, a specialty bio-pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that Dr. Joerg Serafimov has been appointed to the newly created role as Chief Business Officer (CBO), effective January 1, 2024. In this capacity, he is responsible for International Business and Licensing, Key Account Management, Business […]

read more

AMW Expands Leadership Team for Strategic Expansion

Warngau, Germany, November 28, 2023 AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced the expansion of its leadership team to implement its strategic growth strategy. Following Philipp Karbach taking over the role of Chief Executive Officer (CEO) in June this year, Sebastian Herzog now strengthens the management team […]

read more

AMW expands management team for strategic expansion course

Warngau, November 28, 2023 AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today announced the expansion of its management team to implement its strategic growth strategy. After taking over the role of Chief Executive Officer (CEO) from Philipp Karbach in June of this year, Sebastian Herzog is strengthening the management team with […]

read more

AMW Receives first Notified Body Opinion by TÜV SÜD and Lays the Foundation for Further Approvals of Goserelin in the EU

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has achieved a key milestone in opening new markets within the European Union (EU) and beyond with the final report of the first Notified Body Opinion (NBO) for its goserelin implant.

read more

AMW reports financial results for fiscal 2022 and updates on corporate performance

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, today released its financial results for the year ended December 31, 2022. AMW reported record consolidated sales for 2022 of €22.8 million and achieved operating profitability for the first time in the company’s history. The company also reported that Philipp Karbach will assume the position of chief executive officer (CEO) effective June 1, 2023, as Dr. Konstantin Petropoulos has decided to step down as CEO of AMW GmbH effective May 31, 2023, to pursue new opportunities. Philipp Karbach joined AMW in 2016, most recently in his role as Chief Operating Officer (COO) and Chief Financial Officer (CFO).

read more